Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185)

被引：10

作者：

Li, Xin ^{[1
]}

Liu, Minghui ^{[1
]}

Zhang, Hongbing ^{[1
]}

Liu, Hongyu ^{[2
]}

Chen, Jun ^{[1
,2
]}

机构：

[1] Tianjin Med Univ, Tianjin Lung Canc Inst, Dept Lung Canc Surg, Gen Hosp, Tianjin 300052, Peoples R China

[2] Tianjin Med Univ, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Gen Hosp, Tianjin, Peoples R China

来源：

THORACIC CANCER | 2020年 / 11卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Apatinib; EGFR-TKIs; non-small cell lung cancer; slow progression; BEVACIZUMAB; ERLOTINIB; CEA;

D O I：

10.1111/1759-7714.13303

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This clinical trial (ChiCTR1800019185) is designed to be an open-label, prospective, single-center, single arm exploratory research study. The study will recruit non-small cell lung cancer patients (NSCLC) with slow progression after first-line treatment with EGFR-TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression-free survival after EGFR-TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR-TKIs to overcome acquired drug resistance.

引用

页码：819 / 826

页数：8

共 14 条

[1] Costs of bevacizumab and pemetrexed for advanced nonsquamous NSCLC in Italy and Germany [J].

Bosch-Barrera, Joaquim ;

Gil-Bazo, Ignacio .

LUNG CANCER, 2011, 71 (02) :244-244

[2] Recent progress in systemic treatment for lung cancer [J].

Clark, Jeffrey W. ;

Longo, Dan L. .

CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (04) :355-366

[3] Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial [J].

Herbst, Roy S. ;

Ansari, Rafat ;

Bustin, Frederique ;

Flynn, Patrick ;

Hart, Lowell ;

Otterson, Gregory A. ;

Vlahovic, Gordana ;

Soh, Chang-Heok ;

O'Connor, Paula ;

Hainsworth, John .

LANCET, 2011, 377 (9780) :1846-1854

[4] Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) [J].

Kabbinavar, Fairooz ;

Fehrenbacher, Louis ;

Hainsworth, John ;

Kasubhai, Saifuddin ;

Kressel, Bruce ;

Marsland, Thomas ;

Patel, Taral ;

Rubin, Mark ;

White, Leonard ;

Yang, James Chih-Hsin ;

Klughammer, Barbara ;

Colburn, Dawn ;

Miller, Vincent ;

Johnson, Bruce E. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) :1411-1417

[5] Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results [J].

Kato, Terufumi ;

Seto, Takashi ;

Nishio, Makoto ;

Goto, Koichi ;

Yamamoto, Noboru ;

Okamoto, Isamu ;

Tao, Liang ;

Yu, Wei ;

Khaznadar, Tarik ;

Tajima, Kosei ;

Shibata, Masahiko ;

Seki, Akihiro ;

Yamamoto, Nobuyuki .

DRUG SAFETY, 2018, 41 (02) :229-237

[6] Progress and prospects of early detection in lung cancer [J].

Knight, Sean Blandin ;

Crosbie, Phil A. ;

Balata, Haval ;

Chudziak, Jakub ;

Hussell, Tracy ;

Dive, Caroline .

OPEN BIOLOGY, 2017, 7 (09)

[7] Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study [J].

Lin, Chia-Chi ;

Shih, Jin-Yuan ;

Yu, Chong-Jen ;

Ho, Chao-Chi ;

Liao, Wei-Yu ;

Lee, Jih-Hsing ;

Tsai, Tzu-Hsiu ;

Su, Kang-Yi ;

Hsieh, Min-Shu ;

Chang, Yih-Leong ;

Bai, Ya-Ying ;

Huang, Derek De-Rui ;

Thress, Kenneth S. ;

Yang, James Chih-Hsin .

LANCET RESPIRATORY MEDICINE, 2018, 6 (02) :107-116

[8] Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells [J].

Muench, David ;

Rezzoug, Francine ;

Thomas, Shelia D. ;

Xiao, Jingjing ;

Islam, Ashraful ;

Miller, Donald M. ;

Sedoris, Kara C. .

PLOS ONE, 2019, 14 (01)

[9] Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial [J].

Rosell, Rafael ;

Dafni, Urania ;

Felip, Enriqueta ;

Curioni-Fontecedro, Alessandra ;

Gautschi, Oliver ;

Peters, Solange ;

Massuti, Bartomeu ;

Palmero, Ramon ;

Ponce Aix, Santiago ;

Carcereny, Enric ;

Frueh, Martin ;

Pless, Miklos ;

Popat, Sanjay ;

Kotsakis, Athanasios ;

Cuffe, Sinead ;

Bidoli, Paolo ;

Favaretto, Adolfo ;

Froesch, Patrizia ;

Reguart, Noemi ;

Puente, Javier ;

Coate, Linda ;

Barlesi, Fabrice ;

Rauch, Daniel ;

Thomas, Michael ;

Camps, Carlos ;

Gomez-Codina, Jose ;

Majem, Margarita ;

Porta, Rut ;

Shah, Riyaz ;

Hanrahan, Emer ;

Kammler, Roswitha ;

Ruepp, Barbara ;

Rabaglio, Manuela ;

Kassapian, Marie ;

Karachaliou, Niki ;

Tam, Rachel ;

Shames, David S. ;

Molina-Vila, Miguel A. ;

Stahel, Rolf A. .

LANCET RESPIRATORY MEDICINE, 2017, 5 (05) :435-444

[10] Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients [J].

Sone, Kazuki ;

Oguri, Tetsuya ;

Ito, Keima ;

Kitamura, Yuki ;

Inoue, Yoshitsugu ;

Takeuchi, Akira ;

Fukuda, Satoshi ;

Takakuwa, Osamu ;

Maeno, Ken ;

Asano, Takamitsu ;

Kanemitsu, Yoshihiro ;

Ohkubo, Hirotsugu ;

Takemura, Masaya ;

Ito, Yutaka ;

Niimi, Akio .

ANTICANCER RESEARCH, 2017, 37 (09) :5125-5131

← 1 2 →